Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019

Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Satoshi Ide, Sho Saito, Tsubasa Akazawa, Takahito Furuya, Junichi Masuda, Maki Nagashima, Yusuke Asai, Tatsunori Ogawa, Ryohei Yamamoto, Haruhiko Ishioka, Kohei Kanda, Ayako Okuhama, Yuji Wakimoto, Tetsuya Suzuki, Yutaro Akiyama, Yusuke Miyazato, Keiji Nakamura, Takato Nakamoto, Hidetoshi Nomoto, Yuki Moriyama, Masayuki Ota, Shinichiro Morioka, Wataru Matsuda, Tatsuki Uemura, Kentaro Kobayashi, Ryo Sasaki, Daisuke Katagiri, Satoshi Kutsuna, Kayoko Hayakawa, Norio Ohmagari
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Remdesivir Severe COVID-19 Extracorporeal membrane oxygenation Pharmacokinetics analysis Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/460b8a8db4254010b8c675bebb5d2ae4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019

Ejemplares similares